Grifols SA
NASDAQ:GRFS
Intrinsic Value
Grifols SA engages in the production of plasma derivatives. [ Read More ]
The intrinsic value of one GRFS stock under the Base Case scenario is 24.32 USD. Compared to the current market price of 6.41 USD, Grifols SA is Undervalued by 74%.
Valuation Backtest
Grifols SA
Run backtest to discover the historical profit from buying and selling GRFS stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Grifols SA
Current Assets | 6.5B |
Cash & Short-Term Investments | 669.8m |
Receivables | 815m |
Other Current Assets | 5B |
Non-Current Assets | 15B |
Long-Term Investments | 711.6m |
PP&E | 4.2B |
Intangibles | 9.6B |
Other Non-Current Assets | 450.8m |
Current Liabilities | 2.3B |
Accounts Payable | 813.1m |
Other Current Liabilities | 1.5B |
Non-Current Liabilities | 13.3B |
Long-Term Debt | 9.2B |
Other Non-Current Liabilities | 4.1B |
Earnings Waterfall
Grifols SA
Revenue
|
6.6B
EUR
|
Cost of Revenue
|
-4.1B
EUR
|
Gross Profit
|
2.5B
EUR
|
Operating Expenses
|
-1.8B
EUR
|
Operating Income
|
735.7m
EUR
|
Other Expenses
|
-676.3m
EUR
|
Net Income
|
59.3m
EUR
|
Free Cash Flow Analysis
Grifols SA
What is Free Cash Flow?
GRFS Profitability Score
Profitability Due Diligence
Grifols SA's profitability score is 49/100. The higher the profitability score, the more profitable the company is.
Score
Grifols SA's profitability score is 49/100. The higher the profitability score, the more profitable the company is.
GRFS Solvency Score
Solvency Due Diligence
Grifols SA's solvency score is 32/100. The higher the solvency score, the more solvent the company is.
Score
Grifols SA's solvency score is 32/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
GRFS Price Targets Summary
Grifols SA
According to Wall Street analysts, the average 1-year price target for GRFS is 14.69 USD with a low forecast of 5.66 USD and a high forecast of 23.39 USD.
Shareholder Return
GRF Price
Grifols SA
Average Annual Return | -13.37% |
Standard Deviation of Annual Returns | 30.95% |
Max Drawdown | -79% |
Market Capitalization | 5.6B EUR |
Shares Outstanding | 678 410 694 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Grifols SA engages in the production of plasma derivatives. The company is headquartered in Barcelona, Barcelona and currently employs 23,233 full-time employees. The company went IPO on 2006-05-17. The company organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Bio Supplies provides, mostly, biological products for non-therapeutic use. Others provides manufacturing services to third party companies.
Contact
IPO
Employees
Officers
The intrinsic value of one GRFS stock under the Base Case scenario is 24.32 USD.
Compared to the current market price of 6.41 USD, Grifols SA is Undervalued by 74%.